Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Investment
    • Alphabet's GV leads...

    Alphabet's GV leads $58.5 million investment to launch Verve Therapeutics

    GarimaWritten by Garima Published On 2019-05-09T09:15:28+05:30  |  Updated On 9 May 2019 9:15 AM IST
    Alphabets GV leads $58.5 million investment to launch Verve Therapeutics

    Verve Therapeutics plans to target adults at risk of coronary artery disease, the leading cause of death worldwide, by editing their genes to mirror those of people whose naturally occurring genes have been associated with a lower risk of heart disease and heart attacks.


    New Delhi: GV, Alphabet Inc's venture capital arm, led a $58.5 million investment to launch Verve Therapeutics, new biotech focused on developing therapies that edit the human genome to treat heart diseases.


    Gene editing therapies are seen to have huge scope in treating a range of diseases but none are currently approved. Additionally, concerns about safety and the permanent harmful effects the editing could have on humans persist.


    It will be years before Verve is able to market its therapies, but the company intends to use funds from its Series A to begin early testing in animals.


    Read Also: Netmeds acquires health tech startup KiViHealth with Rs 70 crore investment commitment


    The company said it will only develop treatments that involve editing adult cells, so the effects of genetic manipulation cannot be passed on to future generations.


    Verve plans to target adults at risk of coronary artery disease, the leading cause of death worldwide, by editing their genes to mirror those of people whose naturally occurring genes have been associated with a lower risk of heart disease and heart attacks.


    "Poor adherence, costs, side effects, limited access... all these challenges have limited the impact existing heart medications like cholesterol-lowering statins have had," Sekar Kathiresan, who will take over as chief executive officer in July, told Reuters.


    Read Also: Strides to exit investment in Arrow Pharma for over Rs 2000 crore


    "With our therapy, we could change the treatment paradigm for heart disease from chronic care, daily pills or monthly injections to a one-and-done approach."


    Besides Alphabet's GV, other investors included ARCH Venture Partners, F-Prime Capital and Biomatics Capital, the company said on Tuesday.

    Alphabets GVARCH Venture PartnersBiomatics Capitalcardiaccholesterol-lowering statinscoronary artery diseaseF-Prime CapitalfundinggeneGene editing therapiesheart attacksheart diseaseshuman genomeSekar KathiresantreatVerve Therapeutics
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok